View Future GrowthKDA Group 過去の業績過去 基準チェック /06KDA Groupの収益は年間平均-24.2%の割合で減少していますが、 Healthcare Services業界の収益は年間 増加しています。収益は年間20.5% 78.9%割合で 減少しています。主要情報-24.16%収益成長率-16.60%EPS成長率Healthcare Services 業界の成長1.72%収益成長率-78.94%株主資本利益率-105.76%ネット・マージン-2,102.61%前回の決算情報31 Jan 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 07+ 1 more updateKDA Group Inc. Announces Settlement of Judicial ClaimsKDA Group Inc. announced that it has settled a dispute with a former executive officer of the Corporation who claimed from the Corporation a total of $808,191 plus interest and expenses, as well as the issuance of 1,000,000 shares of the capital stock of the Corporation pursuant to his employment contract terminated by the Corporation in July 2022. The Corporation, for its part, was claiming a total of $474,200 plus interest and costs from this former executive. The parties settled this dispute, and the Court ratified the settlement on May 4, 2026. Pursuant to the Settlement, the Corporation has agreed to pay the former executive compensation on May 31, 2026, in the amount of $215,000 payable as follows: (i) the payment of $190,000 and (ii) the issuance of 250,000 common shares at a value of $0.10 per share. The Corporation must obtain the approval of the TSX Venture Exchange for the issuance of these shares, and they will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable securities regulations. The Corporation also announces that it has settled, on March 23, 2026, another dispute involving a former executive who claimed $760,000 from the Corporation under the terms of his employment contract terminated by the Corporation in September 2021. Pursuant to the settlement, the Corporation has agreed to pay the former executive an amount of $215,000 payable on or before April 24, 2026.お知らせ • Mar 05KDA Group Inc., Annual General Meeting, Apr 29, 2026KDA Group Inc., Annual General Meeting, Apr 29, 2026. Location: quebec, quebec city Canadaお知らせ • Mar 03+ 1 more updateKDA Group Inc. Announces Executive and Board ChangesKDA Group Inc. announced the appointment of Mr. Jean-Marc Léveillé as President and Chairman of the Board of Directors of KDA effective February 27, 2026. The Corporation announced the departure of its former President, Marc Lemieux, who will remain a director of the Company until the next shareholders' meeting. Mr. Léveillé has been a director of KDA since February 20, 2025, and has the experience and leadership necessary to ensure the Corporation's transition from the development phase of its healthcare technology products to the large-scale commercialization phase. Jean-Marc Léveillé is a CRIA Fellow with a background in organizational transformation, modern governance, and strategic talent management in highly specialized sectors. A former member of senior management and head of human resources at Marine Industrie (Vickers division) in the naval sector and at Héroux-Devtek in the aerospace sector, he contributed to the reorganization and transformation of these companies to world-class standards, where technical and specialized skills were at the heart of business strategies. As president of Élitis Pharma, Dotemtex Executive Search, Dotemtex Transition, and Prosygma, Mr. Léveillé has spent more than 20 years assisting public, private, and parapublic organizations in modernizing their governance, optimizing their performance, and managing strategic succession. He has also directed the Quebec Philharmonic Orchestra.お知らせ • May 30KDA Group Inc. announced that it has received CAD 2.2 million in fundingKDA Group Inc announced a private placement to issue 8,800,000 units at a price of CAD 0.25 per Unit for total gross proceeds of CAD 2,200,000 on May 29, 2025. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. The transaction included participation from accredited investors. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Insider, Marc Lemieux purchased 80,000 Units for a total consideration of CAD 20,000. Marc Lemieux is hereinafter referred to as the “Insider”. No finder’s fee nor commission are payable in connection with the Private Placement.お知らせ • May 22KDA Group Inc. Receives DSQ Certification for Adherize+ PlatformKDA Group Inc. announced that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Sante Quebec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hopital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management.お知らせ • Apr 16KDA Group Inc. Reaches Final Certification Phase for Medherize with Dossier Sante QuebecKDA Group Inc. announced that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Sante Quebec ("DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024, all three required development phases for the module have now been completed. On April 7, 2025, the Direction des produces de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22-24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025, at the St-Sacrement Hospital Center in Quebec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Quebec to successfully certify for DSQ integration using the granular data mode--a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error.お知らせ • Feb 25KDA Group Inc. Approves the Appointment of Jean-Marc Léveillé as Members of the Audit CommitteeKDA Group Inc. at its annual general meeting of shareholders held on February 20, 2025 approved the appointment of Jean-Marc Léveillé as members of the Corporation's audit committee.お知らせ • Dec 24KDA Group Inc., Annual General Meeting, Feb 20, 2025KDA Group Inc., Annual General Meeting, Feb 20, 2025. Location: quebec, quebec Canadaお知らせ • Jun 13KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast CancerKDA Group Inc. announced the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up. Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA's new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers. Key Features of Medherize: Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients' health status, enabling rapid intervention when needed. Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitor. Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. Analysis and Reporting. Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. This pilot project, the first of its kind, will be deployed in the Corporation's partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion.お知らせ • Mar 16KDA Group Inc., Annual General Meeting, May 16, 2024KDA Group Inc., Annual General Meeting, May 16, 2024.お知らせ • Dec 09KDA Group Inc. announced that it has received CAD 1.125 million in fundingKDA Group Inc. announced a private placement to issue 11,250,000 units at an issue price of CAD 0.10 per unit for the gross proceeds of CAD 1.250,000 on December 8, 2023. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.15 per Common share for a period of 24 months ending December 8, 2025. The transaction included participation from accredited investors. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on April 9, 2024 in accordance with applicable securities regulations. No finder’s fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange.お知らせ • Jun 29KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 27, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities.収支内訳KDA Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:KDAG.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Jan 260-75031 Oct 250-75031 Jul 250-86030 Apr 250-85031 Jan 250-84031 Oct 240-74031 Jul 240-73030 Apr 240-14031 Jan 24004031 Oct 23004031 Jul 23013030 Apr 230-54031 Jan 230-74031 Oct 22-5-83031 Jul 220-94030 Apr 227-63031 Jan 2213-44031 Oct 2125-16031 Jul 212415030 Apr 2123-14031 Jan 2122-13031 Oct 2023-14031 Jul 2023-45030 Apr 2024-76031 Jan 2024-86031 Oct 1924-106031 Jul 1923-85030 Apr 1922-35031 Jan 1921-35031 Oct 1821-14031 Jul 182004030 Apr 1823-64031 Jan 1825-44031 Oct 1727-65031 Jul 1730-87030 Apr 1723-56031 Jan 1719-55031 Oct 1612-44031 Jul 168-12030 Apr 168-12031 Jan 168-12031 Oct 157-12031 Jul 156-120質の高い収益: KDAG.Fは現在利益が出ていません。利益率の向上: KDAG.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: KDAG.Fは利益が出ておらず、過去 5 年間で損失は年間24.2%の割合で増加しています。成長の加速: KDAG.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: KDAG.Fは利益が出ていないため、過去 1 年間の収益成長をHealthcare Services業界 ( 4.2% ) と比較することは困難です。株主資本利益率高いROE: KDAG.Fは現在利益が出ていないため、自己資本利益率 ( -105.76% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 22:03終値2026/05/07 00:00収益2026/01/31年間収益2025/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KDA Group Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 07+ 1 more updateKDA Group Inc. Announces Settlement of Judicial ClaimsKDA Group Inc. announced that it has settled a dispute with a former executive officer of the Corporation who claimed from the Corporation a total of $808,191 plus interest and expenses, as well as the issuance of 1,000,000 shares of the capital stock of the Corporation pursuant to his employment contract terminated by the Corporation in July 2022. The Corporation, for its part, was claiming a total of $474,200 plus interest and costs from this former executive. The parties settled this dispute, and the Court ratified the settlement on May 4, 2026. Pursuant to the Settlement, the Corporation has agreed to pay the former executive compensation on May 31, 2026, in the amount of $215,000 payable as follows: (i) the payment of $190,000 and (ii) the issuance of 250,000 common shares at a value of $0.10 per share. The Corporation must obtain the approval of the TSX Venture Exchange for the issuance of these shares, and they will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable securities regulations. The Corporation also announces that it has settled, on March 23, 2026, another dispute involving a former executive who claimed $760,000 from the Corporation under the terms of his employment contract terminated by the Corporation in September 2021. Pursuant to the settlement, the Corporation has agreed to pay the former executive an amount of $215,000 payable on or before April 24, 2026.
お知らせ • Mar 05KDA Group Inc., Annual General Meeting, Apr 29, 2026KDA Group Inc., Annual General Meeting, Apr 29, 2026. Location: quebec, quebec city Canada
お知らせ • Mar 03+ 1 more updateKDA Group Inc. Announces Executive and Board ChangesKDA Group Inc. announced the appointment of Mr. Jean-Marc Léveillé as President and Chairman of the Board of Directors of KDA effective February 27, 2026. The Corporation announced the departure of its former President, Marc Lemieux, who will remain a director of the Company until the next shareholders' meeting. Mr. Léveillé has been a director of KDA since February 20, 2025, and has the experience and leadership necessary to ensure the Corporation's transition from the development phase of its healthcare technology products to the large-scale commercialization phase. Jean-Marc Léveillé is a CRIA Fellow with a background in organizational transformation, modern governance, and strategic talent management in highly specialized sectors. A former member of senior management and head of human resources at Marine Industrie (Vickers division) in the naval sector and at Héroux-Devtek in the aerospace sector, he contributed to the reorganization and transformation of these companies to world-class standards, where technical and specialized skills were at the heart of business strategies. As president of Élitis Pharma, Dotemtex Executive Search, Dotemtex Transition, and Prosygma, Mr. Léveillé has spent more than 20 years assisting public, private, and parapublic organizations in modernizing their governance, optimizing their performance, and managing strategic succession. He has also directed the Quebec Philharmonic Orchestra.
お知らせ • May 30KDA Group Inc. announced that it has received CAD 2.2 million in fundingKDA Group Inc announced a private placement to issue 8,800,000 units at a price of CAD 0.25 per Unit for total gross proceeds of CAD 2,200,000 on May 29, 2025. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. The transaction included participation from accredited investors. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Insider, Marc Lemieux purchased 80,000 Units for a total consideration of CAD 20,000. Marc Lemieux is hereinafter referred to as the “Insider”. No finder’s fee nor commission are payable in connection with the Private Placement.
お知らせ • May 22KDA Group Inc. Receives DSQ Certification for Adherize+ PlatformKDA Group Inc. announced that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Sante Quebec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hopital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management.
お知らせ • Apr 16KDA Group Inc. Reaches Final Certification Phase for Medherize with Dossier Sante QuebecKDA Group Inc. announced that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Sante Quebec ("DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024, all three required development phases for the module have now been completed. On April 7, 2025, the Direction des produces de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22-24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025, at the St-Sacrement Hospital Center in Quebec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Quebec to successfully certify for DSQ integration using the granular data mode--a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error.
お知らせ • Feb 25KDA Group Inc. Approves the Appointment of Jean-Marc Léveillé as Members of the Audit CommitteeKDA Group Inc. at its annual general meeting of shareholders held on February 20, 2025 approved the appointment of Jean-Marc Léveillé as members of the Corporation's audit committee.
お知らせ • Dec 24KDA Group Inc., Annual General Meeting, Feb 20, 2025KDA Group Inc., Annual General Meeting, Feb 20, 2025. Location: quebec, quebec Canada
お知らせ • Jun 13KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast CancerKDA Group Inc. announced the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up. Medherize marks the first collaboration among specialist doctors, pharmacists and patients to offer integrated and coordinated care. KDA's new clinical management solution is designed to address the complex challenges associated with the administration of CDK 4/6 inhibitors, essential medications in the treatment of certain types of breast cancer. This innovative technology offers an integrated platform enabling healthcare professionals to accurately monitor patient treatments, track side effects and adjust doses in real-time while ensuring seamless communication between patients and care providers. Key Features of Medherize: Personalized Patient Follow-Up: An intuitive user interface allowing doctors to personalize and track treatment plans for each patient, ensuring better adherence to prescribed therapies. Real-Time Monitoring: Integration of monitoring devices that collect real-time data on patients' health status, enabling rapid intervention when needed. Side Effect Management: A proactive notification system to monitor and manage potential side effects of CDK 4/6 inhibitor. Optimized Communication: A secure communication platform facilitating exchanges between patients, doctors and pharmacists, thereby enhancing care coordination. Analysis and Reporting. Advanced analytical tools to generate detailed reports on treatment effectiveness, supporting evidence-based clinical decision-making. This pilot project, the first of its kind, will be deployed in the Corporation's partner clinics and hospitals in the coming months, with ambitions to expand internationally. KDA remains committed to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-edge solutions that meet the evolving needs of the healthcare sector. Artificial intelligence and new technologies could reduce healthcare spending by $200 to $360 billion.
お知らせ • Mar 16KDA Group Inc., Annual General Meeting, May 16, 2024KDA Group Inc., Annual General Meeting, May 16, 2024.
お知らせ • Dec 09KDA Group Inc. announced that it has received CAD 1.125 million in fundingKDA Group Inc. announced a private placement to issue 11,250,000 units at an issue price of CAD 0.10 per unit for the gross proceeds of CAD 1.250,000 on December 8, 2023. Each Unit consists of one Class A Share and one Common share purchase warrant. Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of CAD 0.15 per Common share for a period of 24 months ending December 8, 2025. The transaction included participation from accredited investors. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one day hold period expiring on April 9, 2024 in accordance with applicable securities regulations. No finder’s fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange.
お知らせ • Jun 29KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.KDA Group Inc. (TSXV:KDA) entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million on June 27, 2023. The consideration will be paid through the issuance of 10,000,000 Class A shares in the share capital of KDA Group. ZoomMed Board of Directors has unanimously approved an agreement for the sale. The transaction will be completed following the satisfaction or waiver of all closing conditions provided for in the asset purchase agreement, including the approval by the shareholders of the ZoomMed and obtaining the approvals from applicable regulatory authorities.